<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585194</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0919</org_study_id>
    <secondary_id>NCI-2015-00853</secondary_id>
    <secondary_id>NCI-2012-00665</secondary_id>
    <secondary_id>2011-0919</secondary_id>
    <secondary_id>R21CA208609</secondary_id>
    <nct_id>NCT01585194</nct_id>
  </id_info>
  <brief_title>Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma</brief_title>
  <official_title>Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well nivolumab and ipilimumab work in treating patients with&#xD;
      uveal melanoma that has spread to other places in the body (metastatic). Immunotherapy with&#xD;
      monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system&#xD;
      attack the cancer, and may interfere with the ability of tumor cells to grow and spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Overall response rate.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Progression-free survival. II. Median overall survival. III. One-year overall survival.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Tissue and blood correlates to define immune infiltration and signatures as a result of&#xD;
      treatment with nivolumab plus ipilimumab.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION PHASE: Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab&#xD;
      IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by&#xD;
      week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 60 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate, Defined Per RECIST 1.1</measure>
    <time_frame>Up to 2 years of treatment plus 60 days from last study dose</time_frame>
    <description>RECIST 1.1 response is defined as &gt;=30% reduction in sum of the longest diameter of target lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From date of enrollment until the date of progressive disease or date of death from any cause, whichever came first, and assessed up to 60 days after completion of study treatment, a median of 13.0 months</time_frame>
    <description>Time from enrollment to progressive disease or death. Progressive disease is defined per RECIST 1.1 as &gt;=20% increase in the sum of the longest diameter of target lesions from nadir, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of enrollment until the date of death from any cause, a median of 13.0 months</time_frame>
    <description>Measured from time of enrollment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Overall Survival</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>Measured as percentage of patients alive at 1 year from enrollment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Metastatic Uveal Melanoma</condition>
  <condition>Stage IV Uveal Melanoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (nivolumab, ipilimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nivolumab, ipilimumab)</arm_group_label>
    <other_name>Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA4</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nivolumab, ipilimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nivolumab, ipilimumab)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to give written informed consent&#xD;
&#xD;
          -  History of uveal melanoma and documented metastatic disease with at least one&#xD;
             measurable lesion is required; which is &gt;= 1 cm x 1 cm (on spiral computed tomography&#xD;
             [CT] or equivalent)&#xD;
&#xD;
          -  Any number of prior therapies is allowed&#xD;
&#xD;
          -  White blood cell (WBC) &gt;= 2000/uL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^3/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) &gt; 40&#xD;
             mL/min (using the Cockcroft-Gault formula)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 3 x ULN for&#xD;
             patients without liver metastasis, =&lt; 5 x ULN for liver metastases&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x ULN, (except patients with Gilbert's syndrome, who must have a&#xD;
             total bilirubin less than 3.0 mg/dL)&#xD;
&#xD;
          -  In suspected patients no active or chronic infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B, or hepatitis C&#xD;
&#xD;
          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Baseline imaging in the form of CT chest, abdomen, pelvis with oral and intravenous&#xD;
             contrast within 28 days of study entry; for patients with a contrast allergy, choice&#xD;
             of alternative body imaging will be at the discretion of the investigator or his&#xD;
             designee; magnetic resonance imaging (MRI) of the brain is only needed if clinically&#xD;
             indicated&#xD;
&#xD;
          -  Prior to start of treatment must be more than 21 days elapsed from surgery, radiation&#xD;
             therapy, or prior chemotherapy; more than 42 days elapsed from prior immune therapy&#xD;
             including vaccines&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and fertile men with partners of childbearing&#xD;
             potential must be using an adequate method of contraception to avoid pregnancy&#xD;
             throughout the study and for up to 26 weeks after the last dose of investigational&#xD;
             product, in such a manner that the risk of pregnancy is minimized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated primary uveal melanoma except in cases where metastatic disease is diagnosed&#xD;
             at the time of primary disease&#xD;
&#xD;
          -  Metastatic uveal melanoma patients with bone-only disease&#xD;
&#xD;
          -  Any other malignancy from which the patient has been disease-free for less than 2&#xD;
             years, with the exception of adequately treated and cured basal or squamous cell skin&#xD;
             cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or&#xD;
             prostate&#xD;
&#xD;
          -  Autoimmune disease: Patients with a history of inflammatory bowel disease, including&#xD;
             ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients&#xD;
             with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic&#xD;
             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune&#xD;
             vasculitis [e.g., Wegener's Granulomatosis]; motor neuropathy considered of autoimmune&#xD;
             origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis)&#xD;
&#xD;
          -  Any underlying medical or psychiatric condition, which in the opinion of the&#xD;
             investigator will make the administration of ipilimumab hazardous or obscure the&#xD;
             interpretation of adverse events (AEs), such as a condition associated with frequent&#xD;
             diarrhea&#xD;
&#xD;
          -  Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to&#xD;
             1 month before or after any dose of ipilimumab)&#xD;
&#xD;
          -  Concomitant therapy with any of the following: tamoxifen, toremifene, IL 2,&#xD;
             interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy;&#xD;
             immunosuppressive agents; other investigation therapies; or chronic use of systemic&#xD;
             corticosteroids greater than physiologic replacement doses; ocular steroid use is&#xD;
             acceptable; (a) concomitant palliative radiation for the purposes of symptom&#xD;
             management is allowed&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) who: (a) are unwilling or unable to use an&#xD;
             acceptable method of contraception to avoid pregnancy for their entire study period&#xD;
             and for up to 26 weeks after cessation of study drug, or (b) have a positive pregnancy&#xD;
             test at baseline, or (c) are pregnant or breastfeeding&#xD;
&#xD;
          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious) illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sapna Patel</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT01585194/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The accrual goal and dates were updated to match the new statistical design 10/2017.The enrollment changed to 39 participants. A total of 67 participants signed consent, 39 participants entered the study to participate in the trial in its current form w/combination metastatic therapy. 28 patients entered the study in its previous form when it was an adjuvant trial and then subsequently a monotherapy metastatic trial, and they are inevaluable for reporting results of the study in its current form</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Nivolumab, Ipilimumab)</title>
          <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of insurance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Nivolumab, Ipilimumab)</title>
          <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate, Defined Per RECIST 1.1</title>
        <description>RECIST 1.1 response is defined as &gt;=30% reduction in sum of the longest diameter of target lesions</description>
        <time_frame>Up to 2 years of treatment plus 60 days from last study dose</time_frame>
        <population>5 patients not analyzed due to lack of follow-up efficacy imaging</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Nivolumab, Ipilimumab)</title>
            <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate, Defined Per RECIST 1.1</title>
          <description>RECIST 1.1 response is defined as &gt;=30% reduction in sum of the longest diameter of target lesions</description>
          <population>5 patients not analyzed due to lack of follow-up efficacy imaging</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>Time from enrollment to progressive disease or death. Progressive disease is defined per RECIST 1.1 as &gt;=20% increase in the sum of the longest diameter of target lesions from nadir, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>From date of enrollment until the date of progressive disease or date of death from any cause, whichever came first, and assessed up to 60 days after completion of study treatment, a median of 13.0 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Nivolumab, Ipilimumab)</title>
            <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>Time from enrollment to progressive disease or death. Progressive disease is defined per RECIST 1.1 as &gt;=20% increase in the sum of the longest diameter of target lesions from nadir, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.4" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Measured from time of enrollment to death</description>
        <time_frame>From date of enrollment until the date of death from any cause, a median of 13.0 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Nivolumab, Ipilimumab)</title>
            <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Measured from time of enrollment to death</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="9.6" upper_limit="NA">The upper limit 95% Confidence Interval on Secondary Outcome Overall Survival as not enough &quot;events&quot; (deaths) have occurred past the median to calculate this upper limit of measure of dispersion.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-year Overall Survival</title>
        <description>Measured as percentage of patients alive at 1 year from enrollment</description>
        <time_frame>Baseline up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Nivolumab, Ipilimumab)</title>
            <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Overall Survival</title>
          <description>Measured as percentage of patients alive at 1 year from enrollment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to 60 days after last dose of study drug, a median of 13.0 months</time_frame>
      <desc>From baseline to 60 days after last dose of drug, a median of 13.0 months</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Nivolumab, Ipilimumab)</title>
          <description>INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
Ipilimumab: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Nivolumab: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sapna P. Patel/Associate Professor, Melanoma Medical Oncology</name_or_title>
      <organization>MD Anderson Cancer Center</organization>
      <phone>713-792-2921</phone>
      <email>sppatel@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

